March 22 (Reuters) - A panel of U.S. Food and Drug Administration (FDA) advisers on Wednesday voted against the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS). (Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.09 USD | +0.19% | +2.99% | -14.83% |
11/04 | North American Morning Briefing : Stock Futures -2- | DJ |
10/04 | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
213.5 USD | -1.21% | +5.46% | 31.47B | ||
43.09 USD | +0.19% | +2.99% | 6.27B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.83% | 6.27B | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- US FDA panel votes against effectiveness of Biogen's ALS drug